<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Kpenu EK</submitter><funding>NCI NIH HHS</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Pancreatic ductal adenocarcinoma (PDAC) is a highly deadly cancer with limited treatment options. The base excision repair (BER) pathway, crucial for fixing DNA abasic sites, is driven by apurinic/apyrimidinic endonuclease 1 (APE1). While APE1's redox function has been extensively studied, its endonuclease activity in PDAC homeostasis and therapeutic response remains poorly understood. We created stable, homozygous APE1 endonuclease-reduced PDAC cell lines to examine the effects of impaired BER activity on pancreatic cancer growth, progression, and response to treatment.&lt;h4>Methods&lt;/h4>CRISPR/Cas9-mediated editing was used to introduce an E96A mutation into the Pa03C PDAC cell line, generating three clonal mutant cell lines: E96A B1, E96A B4, E96A G8. APE1 expression and</pubmed_abstract><journal>Research square</journal><pagination>rs.3.rs-8197122</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12776480</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancer.</pubmed_title><pmcid>PMC12776480</pmcid><funding_grant_id>R01 CA282478</funding_grant_id><funding_grant_id>R01 CA254110</funding_grant_id><funding_grant_id>P30 CA082709</funding_grant_id><funding_grant_id>U01 CA274304</funding_grant_id><pubmed_authors>Kelley MR</pubmed_authors><pubmed_authors>Haiaty S</pubmed_authors><pubmed_authors>Peil J</pubmed_authors><pubmed_authors>Wireman RS</pubmed_authors><pubmed_authors>Liu S</pubmed_authors><pubmed_authors>Kpenu EK</pubmed_authors><pubmed_authors>Gampala S</pubmed_authors><pubmed_authors>Sharma A</pubmed_authors><pubmed_authors>Mijiti M</pubmed_authors><pubmed_authors>Sardar R</pubmed_authors><pubmed_authors>Fishel ML</pubmed_authors><pubmed_authors>Wan J</pubmed_authors><pubmed_authors>Mitchell DK</pubmed_authors><pubmed_authors>Georgiadis MM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeting APE1 endonuclease activity impairs metastasis and enhances genotoxic therapy response in pancreatic cancer.</name><description>&lt;h4>Background&lt;/h4>Pancreatic ductal adenocarcinoma (PDAC) is a highly deadly cancer with limited treatment options. The base excision repair (BER) pathway, crucial for fixing DNA abasic sites, is driven by apurinic/apyrimidinic endonuclease 1 (APE1). While APE1's redox function has been extensively studied, its endonuclease activity in PDAC homeostasis and therapeutic response remains poorly understood. We created stable, homozygous APE1 endonuclease-reduced PDAC cell lines to examine the effects of impaired BER activity on pancreatic cancer growth, progression, and response to treatment.&lt;h4>Methods&lt;/h4>CRISPR/Cas9-mediated editing was used to introduce an E96A mutation into the Pa03C PDAC cell line, generating three clonal mutant cell lines: E96A B1, E96A B4, E96A G8. APE1 expression and</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-07-05T03:10:17.967Z</modification><creation>2026-07-05T03:08:10.845Z</creation></dates><accession>S-EPMC12776480</accession><cross_references><pubmed>41510226</pubmed><doi>10.21203/rs.3.rs-8197122/v1</doi></cross_references></HashMap>